Clinical Trials Logo

Filter by:
NCT ID: NCT06170437 Not yet recruiting - Tobacco Smoking Clinical Trials

Smoke-free Home Study in Subsidized Housing

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Comprehensive smoke-free policies have the potential to substantially reduce tobacco-related disparities among populations in subsidized housing. This study fills this gap by identifying approaches to increase the implementation of smoke-free policies in all types of subsidized housing by increasing the voluntary adoption of smoke-free homes and promoting access to smoking cessation services.

NCT ID: NCT06176118 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Based on existing literature and clinical trials, 2- hydroxbenzylamine (2-HOBA) has clear impact on mechanisms that much of the international field of pulmonary hypertension (PH) research agrees are central to disease progression. The investigator's preliminary data and Phase I studies demonstrate not only a clear positive impact on reducing pulmonary vascular resistances in Group I and II PH, and both cytokine and molecular biomarkers of disease, but also indicated the potential for a substantial positive effect on heart function under load stress. In this Phase II project, investigators will test the safety and efficacy of 2-HOBA in PH patients, improving the function of the right ventricle under stress in a large animal model, and effectiveness in the context of standard-of-care in mouse models and large animals, to establish the remaining data needed to proceed to commercialization.

NCT ID: NCT06181331 Not yet recruiting - Cancer Clinical Trials

The Effect of a Stepped-care Metacognition-based Intervention on Managing Fear of Cancer Recurrence

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

A sequential multiple-assignment randomized controlled trial (SMART) will be used to assess the effect of an adaptive stepped-care intervention on FCR in cancer survivors with subclinical levels of fear of cancer recurrence.

NCT ID: NCT06184659 Not yet recruiting - Sepsis Clinical Trials

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

EMPRESS
Start date: August 1, 2024
Phase: Phase 4
Study type: Interventional

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

NCT ID: NCT06184828 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Pilot Study of Whole Blood Transfusion for Trauma Brain Injury (TBI)

Start date: August 1, 2024
Phase: Phase 3
Study type: Interventional

Our goal is to perform a pilot, single center study to evaluate the efficacy of whole blood (WB) in subjects with TBI, intracranial hemorrhage, and anemia compared to blood component therapy.

NCT ID: NCT06188741 Not yet recruiting - Neurofibromatosis 1 Clinical Trials

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

NF114
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there remains a critical need in this patient population to determine if young participants with PN in high-risk locations may benefit from early medical intervention prior to the development of clinical problems. This study will determine whether participants with asymptomatic PN in high-risk locations can potentially benefit from early treatment with selumetinib.

NCT ID: NCT06189885 Not yet recruiting - Clinical trials for Periprosthetic Joint Infection

Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second stage of reimplantation of the artificial joint. Methicillin-resistant staphylococcus aureus (MRSA) infection is one of the factors leading to the failure of artificial joint infection treatment. Before the second stage of the joint surgery, the surgeon will prescribe prophylactic antibiotics based on previous bacterial cultures. The usual preoperative antibiotic is a first-generation cephalosporin antibiotic. If it is MRSA, vancomycin will be given. Increasingly, literature reports link prosthetic joint infections to MRSA, but no changes have been made to the routine recommendation for MRSA prophylactic antibiotic use. Daptomycin is a cyclic lipopeptide antibiotic that can rapidly penetrate biofilms and bones, and its safety and tolerability have been confirmed. Therefore, it can effectively combat Gram-positive organisms, including MRSA. Daptomycin has many characteristics of an ideal prophylactic: short infusion time, low adverse events during administration, and a range limited to Gram-positive organisms. We aim to assess whether adding antibiotics that cover MRSA would reduce prosthetic joint infections and increase surgical success rates, in addition to the standard recommended prophylactic antibiotics. Thus, this prospective randomized trial is designed to assess, besides using the first-generation cephalosporin antibiotic, the effects of adding an antibiotic with MRSA coverage (Daptomycin vs. Vancomycin).

NCT ID: NCT06191133 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

NCT ID: NCT06192745 Not yet recruiting - Sleep Clinical Trials

SCREENS: Sleep, Circadian Rhythms, and Electronics in the EveNing Study

SCREENS
Start date: August 1, 2024
Phase: N/A
Study type: Interventional

The proposed project aims to disentangle the impact of evening light exposure emitted from tablet devices from the impact of arousing media content on children's sleep regulation, circadian physiology and next-day emotion regulation and executive functioning.

NCT ID: NCT06193382 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Parent-Child Interaction Therapy (PCIT) for Children With Traumatic Brain Injury (TBI): A Stepped-Care Model

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to understand how a stepped-care model of Parent-Child Interaction Therapy (Step-Up PCIT) addresses child behavioral problems among children between the ages of 2 and 7 with a traumatic brain injury (TBI).